Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer & Thermo Fischer enter NGS testing agreement

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 09, 2023 10:08am

121 Views

Post# 35438331

RE:Pfizer & Thermo Fischer enter NGS testing agreement

Under the agreement, Thermo Fisher will identify local labs that will be using the company's NGS technology and ensure they have the necessary infrastructure, trained staff, and quality control measures to meet industry standards for NGS testing services for breast and lung cancer.

[ So it would appear that Pfizer has moved towards the implementation of biomarker testing that ONCY's Bracelet-1 Phase 2 breast cancer study identified as a predictive diagnostics in the precision treatment of breast cancer ]

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders